Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Egalet, Shionogi Enter Development/License Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Egalet, Shionogi Enter Development/License Agreement

To develop abuse-deterrent oral hydrocodone opioid candidates

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Egalet Corp. has entered into a definitive collaboration and license agreement with Shionogi Ltd. for the development and potential commercialization of multiple oral abuse-deterrent hydrocodone opioid product candidates using Egalet’s technology platform.

Egalet will receive $10 million upfront and is eligible to receive milestone payments of as much as $300 million for development and approval of products under the agreement, as well as royalties on sales that could exceed $100 million. Shionogi will fund all development costs and will have exclusive global commercialization rights. Shionogi has also agreed to purchase as much as $15 million in common stock in a private placement to close concurrently with Egalet’s recently filed IPO.

“With their commitment to pain therapeutics and their strong sales and marketing capabilities, we are pleased to be collaborating with Shionogi for the development and potential commercialization of abuse-deterrent hydrocodone products using our proprietary technology,” said Bob Radie, Egalet’s President and Chief Executive Officer. “We believe this collaboration provides validation for our proprietary abuse-deterrent drug delivery platform and positions us to capitalize on our technology, both through the products to be developed under the collaboration and by enabling us to develop additional opioid candidates utilizing our platform technology.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics